secondary hyperparathyroidism
Endocrinology · 2005–2019
12decisions
3medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| cinacalcet Treatment of secondary hyperparathyroidism in patients with chronic kidney disease receiving dialysis who have not responded to conventional therapy. | Jul 2019 | Recommended with restriction | none received |
| cinacalcet Management of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, not responding to conventional therapy. | Mar 2014 | Not recommended | no section in document |
| cinacalcet Treatment of secondary hyperparathyroidism in dialysis patients with chronic kidney disease, and treatment of hypercalcemia in patients with parathyroid… | Nov 2013 | Recommended | no section in document |
| paricalcitol Treatment of secondary hyperparathyroidism in patients with chronic kidney disease where treatment with calcitriol is not appropriate. | Mar 2011 | Not recommended | no section in document |
| paricalcitol Treatment by a nephrologist of patients with chronic kidney disease (Stage 5) receiving dialysis who have secondary hyperparathyroidism (iPTH value > 300 pg/mL… | Mar 2009 | Not recommended | no section in document |
| paricalcitol Treatment of patients with end stage chronic renal disease receiving dialysis who have secondary hyperparathyroidism. | Mar 2008 | Recommended | no section in document |
| paricalcitol Treatment by a nephrologist of patients with end stage renal disease receiving dialysis who have secondary hyperparathyroidism (iPTH value > 300 pg/mL). | Jul 2007 | Not recommended | no section in document |
| paricalcitol Treatment of secondary hyperparathyroidism in patients with end-stage renal disease receiving dialysis, with intact parathyroid hormone (iPTH) values greater… | Jul 2007 | Not recommended | no section in document |
| cinacalcet hydrochloride for the treatment for up to 6 months, by a nephrologist, for a patient with chronic kidney disease on dialysis who have sustained secondary hyperparathyroidism… | Nov 2007 | Recommended | no section in document |
| cinacalcet hydrochloride Treatment of secondary hyperparathyroidism in patients with end stage renal disease receiving dialysis who have uncontrolled secondary hyperparathyroidism. | Nov 2007 | Recommended with restriction | no section in document |
| cinacalcet hydrochloride use in patients with end stage renal disease receiving dialysis who have uncontrolled secondary hyperparathyroidism (iPTH value > 53 pmol/L (>500 pg/mL)) | Jul 2006 | Not recommended | no section in document |
| cinacalcet hydrochloride Treatment of secondary hyperparathyroidism in patients with end stage renal disease receiving dialysis. | Nov 2005 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.